CD8A and neoplasm: Furthermore, TIM‐3 inhibition was found to cause cDC1‐like mregDCs to take up more tumour antigen and activate the cGAS–STING pathway,83 inducing the release of CXCL9 and IL‐12 from mregDCs and encouraging CD8+ T‐cell colocalisation with DCs to enhance antitumour immunity.84